Genmab, AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study

Reuters2026/10/05 22:09

Adds analyst comment in bullet 3 By Sahil Pandey Oct 5 (Reuters) - Danish biotech firm Genmab GMAB.CO and US drugmaker AbbVie ABBV.N said on Monday their combination treatment for patients newly diagnosed with a type of lymphoma reduced the risk of disease progression or death in a late-stage study. US-listed shares of Genmab GMAB.O were up about 1.04% in extended trading. AbbVie's shares were flat. The study tested epcoritamab in combination with R-CHOP in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma The combination reduced the risk of disease progression or death by 51% in newly diagnosed patients compared with R-CHOP alone, the companies said Barclays analyst Emily Field said the result was a strong validation of epcoritamab in frontline DLBCL, which represents the largest commercial opportunity for the drug Epcoritamab, jointly developed by Genmab and AbbVie, is an immune-based therapy that helps the body's T cells attack cancer cells, while R-CHOP is currently offered as the standard treatment for those with DLBCL The companies said the trial is the first late-stage study of a bispecific antibody combination to significantly improve progression-free survival — how long patients live without their cancer worsening — in first-line DLBCL They said the combination's safety profile was generally consistent with the known safety profiles of epcoritamab and R-CHOP Epcoritamab has not yet been approved for patients who have just been diagnosed and have not received prior treatment (Reporting by Sahil Pandey in Bengaluru; Editing by Diti Pujara) ((Sahil.Pandey@thomsonreuters.com;))

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Adds analyst comment in bullet 3

By Sahil Pandey

Oct 5 (Reuters) - Danish biotech firm Genmab GMAB.CO and US drugmaker AbbVie ABBV.N said on Monday their combination treatment for patients newly diagnosed with a type of lymphoma reduced the risk of disease progression or death in a late-stage study.

US-listed shares of Genmab GMAB.O were up about 1.04% in extended trading. AbbVie's shares were flat.

The study tested epcoritamab in combination with R-CHOP in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma
The combination reduced the risk of disease progression or death by 51% in newly diagnosed patients compared with R-CHOP alone, the companies said
Barclays analyst Emily Field said the result was a strong validation of epcoritamab in frontline DLBCL, which represents the largest commercial opportunity for the drug
Epcoritamab, jointly developed by Genmab and AbbVie, is an immune-based therapy that helps the body's T cells attack cancer cells, while R-CHOP is currently offered as the standard treatment for those with DLBCL
The companies said the trial is the first late-stage study of a bispecific antibody combination to significantly improve progression-free survival — how long patients live without their cancer worsening — in first-line DLBCL
They said the combination's safety profile was generally consistent with the known safety profiles of epcoritamab and R-CHOP
Epcoritamab has not yet been approved for patients who have just been diagnosed and have not received prior treatment

(Reporting by Sahil Pandey in Bengaluru; Editing by Diti Pujara)

((Sahil.Pandey@thomsonreuters.com;))

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.

华尔街见闻•2026/11/09 10:26